For LPs
Fractal invests across the full pediatric continuum from fetal development through young adults (age 26). Early-stage intervention addresses the origin of chronic disease, not its consequences. That is where clinical differentiation is highest, competition is lowest, and the path to a defensible market position is shortest.
Pediatric healthcare represents billions in annual spending across diagnostics, therapeutics, devices, and care delivery. Yet the sector has historically lacked the capital ecosystem that supports innovation in other areas of medicine. This structural imbalance has left a large and durable market significantly undercapitalized.
Despite this, the fundamentals are strong: recurring healthcare expenditure, regulatory pathways that protect defensible innovation, high unmet clinical need, and accelerating adoption of specialized solutions. Companies that succeed in this market build deep clinical differentiation and durable structural advantage.
As innovation accelerates, pediatric healthcare is emerging as a distinct and durable category within venture-backed medicine. Fractal exists to help build and finance that category.
The opportunity requires disciplined capital allocation and deep domain expertise. Fractal invests where clinical necessity meets commercial scalability, targeting venture-scale outcomes within a specialized market.
Our strategy emphasizes concentrated conviction, rigorous domain underwriting, capital efficiency, and long-term company building. We invest not only in companies, but also in the foundational infrastructure required for this category to scale.
Fractal investors join a focused community of physicians, scientists, and experienced venture partners with access to proprietary diligence and early-stage opportunities.
Participation is limited to accredited investors.